These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 33558159)

  • 21. Enfortumab vedotin-ejfv for the treatment of advanced urothelial carcinoma.
    Mantia CM; Sonpavde G
    Expert Rev Anticancer Ther; 2022 May; 22(5):449-455. PubMed ID: 35466857
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recent Advances in the Development of Antibody-Drug Conjugates in Urothelial Cancer.
    Alhalabi O; Altameemi L; Campbell MT; Meric-Bernstam F
    Cancer J; 2022 Nov-Dec 01; 28(6):417-422. PubMed ID: 36383903
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Updates and novel treatments in urothelial carcinoma.
    Hanna KS
    J Oncol Pharm Pract; 2019 Apr; 25(3):648-656. PubMed ID: 30304985
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of enfortumab vedotin and sacituzumab govitecan in treatment of advanced bladder cancer.
    Hanna KS; Larson S; Nguyen J; Boudreau J; Bulin J; Rolf M
    Am J Health Syst Pharm; 2022 Apr; 79(8):629-635. PubMed ID: 34864835
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Trend in overall survival from the start of first-line chemotherapy in patients with metastatic urothelial carcinoma.
    Yamamoto S; Kato M; Matsue T; Yukimatsu N; Takeyama Y; Otoshi T; Yamasaki T; Kuratsukuri K; Uchida J
    Jpn J Clin Oncol; 2024 Feb; 54(2):221-224. PubMed ID: 37886853
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [ANTIBODY-DRUG CONJUGATES - A NOVEL APPROACH FOR THE TREATMENT OF METASTATIC UROTHELIAL CARCINOMA].
    Sternschuss M; Sarfaty M
    Harefuah; 2022 Jan; 161(1):49-54. PubMed ID: 35077061
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Navigating the Rapidly Evolving Advanced Urothelial Carcinoma Treatment Landscape: Insights from Italian Experts.
    Santini D; Banna GL; Buti S; Isella L; Stellato M; Roberto M; Iacovelli R
    Curr Oncol Rep; 2023 Nov; 25(11):1345-1362. PubMed ID: 37855848
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is HER2 the New NECTIN4 in Advanced Urothelial Cancer?
    Nally E; Young M; Wells C; Fairhead R; Baines K; Cheney-Lowe H; Jackson-Spence F; Powles T
    Eur Urol Focus; 2024 Mar; 10(2):219-221. PubMed ID: 38825408
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evolving systemic management of urothelial cancers.
    Tan WS; Tan MY; Alhalabi O; Campbell MT; Kamat AM; Gao J
    Curr Opin Oncol; 2023 May; 35(3):186-199. PubMed ID: 36966497
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Profile of Enfortumab Vedotin in the Treatment of Urothelial Carcinoma: The Evidence to Date.
    Moussa M; Papatsoris A; Abou Chakra M; Dellis A
    Drug Des Devel Ther; 2021; 15():453-462. PubMed ID: 33603337
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibody-drug conjugates for the treatment of urothelial carcinoma.
    Ravi P; McGregor BA
    Expert Opin Biol Ther; 2021 Jul; 21(7):915-922. PubMed ID: 32589063
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Systematic review of recent advancements in antibody-drug and bicycle toxin conjugates for the treatment of urothelial cancer.
    Domb C; Garcia JA; Barata PC; Mendiratta P; Rao S; Brown JR
    Ther Adv Urol; 2024; 16():17562872241249073. PubMed ID: 38779496
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Perspectives on the future of urothelial carcinoma therapy: chemotherapy and beyond.
    Bianchi A; von Deimling M; Pallauf M; Yanagisawa T; Kawada T; Mostafaei H; Quhal F; Laukhtina E; Rajwa P; Majdoub M; Motlagh RS; Pradere B; Karakiewicz PI; Cerruto MA; Antonelli A; Shariat SF
    Expert Opin Pharmacother; 2023 Feb; 24(2):177-195. PubMed ID: 36440477
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The management of toxicities from immune, targeted and ADCs treatments in patients with urothelial cancer.
    Atiq S; Hirshman N; Shariff A; Zhang T
    Urol Oncol; 2023 Oct; 41(10):410-419. PubMed ID: 34973855
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical Overview of Enfortumab Vedotin in the Management of Locally Advanced or Metastatic Urothelial Carcinoma.
    Hanna KS
    Drugs; 2020 Jan; 80(1):1-7. PubMed ID: 31823332
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of enfortumab vedotin in an HIV-positive patient with urothelial carcinoma.
    Azizi A; Houshyar R; Mar N
    J Oncol Pharm Pract; 2022 Jul; 28(5):1226-1229. PubMed ID: 35043748
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The evolving treatment landscape of advanced urothelial carcinoma.
    Andreev-Drakhlin AY; Egoryan G; Shah AY; Msaouel P; Alhalabi O; Gao J
    Curr Opin Oncol; 2021 May; 33(3):221-230. PubMed ID: 33818541
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibody-Drug Conjugates in Uro-Oncology.
    Sigorski D; Różanowski P; Iżycka-Świeszewska E; Wiktorska K
    Target Oncol; 2022 May; 17(3):203-221. PubMed ID: 35567672
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biomarkers of Response to Anti-NECTIN4 Antibody-Drug Conjugate Enfortumab Vedotin in Urothelial Cancer.
    Klümper N; Eckstein M
    Eur Urol Focus; 2024 Mar; 10(2):224-226. PubMed ID: 38631991
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enfortumab-vedotin use for urothelial carcinoma in two patients on hemodialysis.
    Khosla H; Bhatt S; Wang MJ; Gignac G; Mittal K; Patel J
    J Oncol Pharm Pract; 2024 Jul; 30(5):941-944. PubMed ID: 38470473
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.